Buscar
Telix Pharmaceuticals Ltd
TLXAñadir a la lista de seguimiento
11.870USD
+0.030+0.25%
Cierre 07/02, 13:00（ET）Cotizaciones retrasadas 15 min
0.00Cap. mercado
--P/E TTM
Más Datos de Telix Pharmaceuticals Ltd Compañía
Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. It is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Its segments include Therapeutics, Precision Medicine and Telix Manufacturing Solutions. Therapeutics segment develops targeted radionuclide therapies for urologic, neurologic, musculoskeletal and hematological cancers. Precision Medicine segment focuses on bringing diagnostic imaging solutions to market. Precision Medicine segment also includes MedTech and International businesses. Telix Manufacturing Solutions segment is its global network of facilities designed to deliver patient doses worldwide. Its pipeline products include TLX591, TLX250, TLX101, TLX66, TLX592, TLX252, TLX400, Illuccix (68Ga-PSMA-11) and TLX007-CDx.
Información de Telix Pharmaceuticals Ltd
Símbolo de cotizaciónTLX
Nombre de la empresaTelix Pharmaceuticals Ltd
Fecha de salida a bolsaNov 15, 2017
Director ejecutivoOrtiz (Raphaeel)
Número de empleados- -
Tipo de seguridadDepository Receipt
Fin del año fiscal- -
Dirección55 Flemington Road
CiudadMELBOURNE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísAustralia
Código postal3051
Teléfono61390933855
Sitio Webhttps://telixpharma.com/
Símbolo de cotizaciónTLX
Fecha de salida a bolsaNov 15, 2017
Director ejecutivoOrtiz (Raphaeel)
Ejecutivos de Telix Pharmaceuticals Ltd
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Christian P. Behrenbruch, J.D., Ph.D.
Dr. Christian P. Behrenbruch, J.D., Ph.D.
Group Chief Executive Officer, Managing Director, Executive Director
Group Chief Executive Officer, Managing Director, Executive Director
--
--
Dr. Mark Nelson, Ph.D.
Dr. Mark Nelson, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Jann Skinner
Ms. Jann Skinner
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. David Cade
Dr. David Cade
Group Chief Medical Officer
Group Chief Medical Officer
--
--
Mr. Richard Valeix
Mr. Richard Valeix
Group Chief Commercial Officer
Group Chief Commercial Officer
--
--
Ms. Tiffany P. Olson
Ms. Tiffany P. Olson
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Darren Smith, CPA
Mr. Darren Smith, CPA
Group Chief Financial Officer
Group Chief Financial Officer
--
--
Mr. Kevin Richardson
Mr. Kevin Richardson
Chief Executive Officer - Telix Precision Medicine
Chief Executive Officer - Telix Precision Medicine
--
--
Mr. Raphaeel Ortiz
Mr. Raphaeel Ortiz
Chief Executive Officer - Telix International
Chief Executive Officer - Telix International
--
--
Ms. Genevieve Ryan
Ms. Genevieve Ryan
Company Secretary
Company Secretary
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Christian P. Behrenbruch, J.D., Ph.D.
Dr. Christian P. Behrenbruch, J.D., Ph.D.
Group Chief Executive Officer, Managing Director, Executive Director
Group Chief Executive Officer, Managing Director, Executive Director
--
--
Dr. Mark Nelson, Ph.D.
Dr. Mark Nelson, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Jann Skinner
Ms. Jann Skinner
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. David Cade
Dr. David Cade
Group Chief Medical Officer
Group Chief Medical Officer
--
--
Mr. Richard Valeix
Mr. Richard Valeix
Group Chief Commercial Officer
Group Chief Commercial Officer
--
--
Ms. Tiffany P. Olson
Ms. Tiffany P. Olson
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Telix Pharmaceuticals Ltd?
Los cinco principales accionistas de Telix Pharmaceuticals Ltd son: Dr. Christian P. Behrenbruch, J.D., Ph.D.
¿Cuántas instituciones poseen acciones de Telix Pharmaceuticals Ltd (TLX)?
A fecha de 2026Q1, 61 instituciones poseen acciones de Telix Pharmaceuticals Ltd, con un valor de mercado combinado de aproximadamente 1.47M, lo que representa el 0.43% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en 326197.00.